SG11201810423XA - Pd-1 / pd-l1 inhibitors for cancer treatment - Google Patents
Pd-1 / pd-l1 inhibitors for cancer treatmentInfo
- Publication number
- SG11201810423XA SG11201810423XA SG11201810423XA SG11201810423XA SG11201810423XA SG 11201810423X A SG11201810423X A SG 11201810423XA SG 11201810423X A SG11201810423X A SG 11201810423XA SG 11201810423X A SG11201810423X A SG 11201810423XA SG 11201810423X A SG11201810423X A SG 11201810423XA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- street
- new york
- pct
- pfizer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 239000012269 PD-1/PD-L1 inhibitor Substances 0.000 title abstract 2
- 229940121653 pd-1/pd-l1 inhibitor Drugs 0.000 title abstract 2
- 102000008096 B7-H1 Antigen Human genes 0.000 abstract 1
- 108010074708 B7-H1 Antigen Proteins 0.000 abstract 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 abstract 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 235000015244 frankfurter Nutrition 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Saccharide Compounds (AREA)
- Pyrane Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Epoxy Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111111111111111 1111111111111111111111111111111111111111111111111111111111111111111111111 Organization 0 International Bureau (10) International Publication Number (43) International Publication Date .....0\"\"\"1 WO 2017/202744 Al 30 November 2017 (30.11.2017) WIPO I PCT (51) International Patent Classification: C07K 16/28 (2006.01) A61P 35/00 (2006.01) Published: — with international search report (Art. 21(3)) (21) International Application Number: — with sequence listing part of description (Rule 5.2(a)) PCT/EP2017/062213 (22) International Filing Date: 22 May 2017 (22.05.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/341,921 26 May 2016 (26.05.2016) US 62/423,358 17 November 2016 (17.11.2016) US 62/471,459 15 March 2017 (15.03.2017) US (71) Applicants: MERCK PATENT GMBH [DE/DE]; Frank- furter Strasse 250, 64293 Darmstadt (DE). PFIZER INC. [US/US]; 235 East 42nd Street, NEW YORK, NY 10017 (US). (72) Inventors: NUYTEN, Dimitry; 101 Lombard Street, Apt _ 306W, SAN FRANCISCO, CA 94111 (US). MOROZOV, Alexei; c/o Pfizer Inc. 235 East 42nd Street, NEW YORK, NY 10017 (US). WOOLFSON, Adrian; 275 Conover = Street, Apt 4R, BROOKLYN, NEW YORK 11231 (US). = THALL, Aron; 6706 Torenia Trail, SAN DIEGO, CA — — 92130, New York (US). CHIN, Kevin; 4 Huckleberry = Lane, SUDBURY, MA 01776 (US). BRAR, Satjit; 9976 = Fox Meadow Road, SAN DIEGO, CA 92127 (US). Designated States (unless otherwise indicated, for every = (81) _ = kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, = = DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, = HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, = — KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, = = _ _ PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, = SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, = TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = — Designated States (unless otherwise indicated, for every (84) = kind of regional protection available): ARIPO (BW, GH, — GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). = _ 1-1 71' 71' IN ei © ei N (54) Title: PD-1 / PD-L1 INHIBITORS FOR CANCER TREATMENT 1-1 0 (57) : The invention relates to methods of treating cancer in a subject, comprising administering to the subject a therapeutically ei effective amount of an inhibitor of the interaction between the PD-1 receptor and its ligand PD-L1.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662341921P | 2016-05-26 | 2016-05-26 | |
| US201662423358P | 2016-11-17 | 2016-11-17 | |
| US201762471459P | 2017-03-15 | 2017-03-15 | |
| PCT/EP2017/062213 WO2017202744A1 (en) | 2016-05-26 | 2017-05-22 | Pd-1 / pd-l1 inhibitors for cancer treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201810423XA true SG11201810423XA (en) | 2018-12-28 |
Family
ID=58745241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201810423XA SG11201810423XA (en) | 2016-05-26 | 2017-05-22 | Pd-1 / pd-l1 inhibitors for cancer treatment |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20190144545A1 (en) |
| EP (1) | EP3464356A1 (en) |
| JP (1) | JP2019516748A (en) |
| KR (1) | KR20190012201A (en) |
| CN (1) | CN109195989A (en) |
| AU (1) | AU2017269675A1 (en) |
| BR (1) | BR112018073920A2 (en) |
| CA (1) | CA3025391A1 (en) |
| IL (1) | IL263178A (en) |
| MX (1) | MX2018014435A (en) |
| RU (1) | RU2018145184A (en) |
| SG (1) | SG11201810423XA (en) |
| TW (1) | TW201800108A (en) |
| WO (1) | WO2017202744A1 (en) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014012819B1 (en) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | ANTI-PD-L1 ANTIBODY OR ANTIGEN BINDING FRAGMENT AND COMPOSITION |
| US10800846B2 (en) | 2015-02-26 | 2020-10-13 | Merck Patent Gmbh | PD-1/PD-L1 inhibitors for the treatment of cancer |
| WO2016205277A1 (en) | 2015-06-16 | 2016-12-22 | Merck Patent Gmbh | Pd-l1 antagonist combination treatments |
| CA2991976A1 (en) | 2015-07-13 | 2017-01-19 | Cytomx Therapeutics, Inc. | Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof |
| IL265762B2 (en) * | 2016-10-06 | 2024-04-01 | Merck Patent Gmbh | Dosing regimen of avelumab for the treatment of cancer |
| JOP20180040A1 (en) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | Pd-1/pd-l1 inhibitors |
| US11168144B2 (en) | 2017-06-01 | 2021-11-09 | Cytomx Therapeutics, Inc. | Activatable anti-PDL1 antibodies, and methods of use thereof |
| AU2019222644B2 (en) | 2018-02-13 | 2021-04-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| US10899735B2 (en) | 2018-04-19 | 2021-01-26 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| JP7105359B2 (en) | 2018-07-13 | 2022-07-22 | ギリアード サイエンシーズ， インコーポレイテッド | PD-1/PD-L1 inhibitor |
| AU2019366355B2 (en) | 2018-10-24 | 2022-10-13 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| WO2020095184A1 (en) * | 2018-11-05 | 2020-05-14 | Pfizer Inc. | Combinations for treating cancer |
| CN113164599B (en) * | 2018-12-24 | 2023-08-01 | 正大天晴药业集团股份有限公司 | Use of anti-PD-L1 monoclonal antibodies for the treatment of cancer |
| US20220257619A1 (en) | 2019-07-18 | 2022-08-18 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| WO2021016233A1 (en) * | 2019-07-22 | 2021-01-28 | Seagen Inc. | Humanized anti-liv1 antibodies for the treatment of cancer |
| AU2021237718B2 (en) | 2020-03-20 | 2023-09-21 | Gilead Sciences, Inc. | Prodrugs of 4'-C-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| JP2023526783A (en) | 2020-05-05 | 2023-06-23 | テオン セラピューティクス，インク． | Cannabinoid receptor type 2 (CB2) modulators and uses thereof |
| WO2023034530A1 (en) | 2021-09-02 | 2023-03-09 | Teon Therapeutics, Inc. | Methods of improving growth and function of immune cells |
| WO2023081730A1 (en) | 2021-11-03 | 2023-05-11 | Teon Therapeutics, Inc. | 4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide derivatives as cannabinoid cb2 receptor modulators for the treatment of cancer |
| WO2023097211A1 (en) | 2021-11-24 | 2023-06-01 | The University Of Southern California | Methods for enhancing immune checkpoint inhibitor therapy |
| KR20230128690A (en) * | 2022-02-28 | 2023-09-05 | 주식회사 시선테라퓨틱스 | Composition for Preventing or Treating Lung Cancer Comprising Nucleic Acid Complex |
| WO2024015372A1 (en) | 2022-07-14 | 2024-01-18 | Teon Therapeutics, Inc. | Adenosine receptor antagonists and uses thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
| SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP0546073B1 (en) | 1990-08-29 | 1997-09-10 | GenPharm International, Inc. | production and use of transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| AU3178993A (en) | 1991-11-25 | 1993-06-28 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| EP1978033A3 (en) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
| CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| ES2301183T3 (en) | 1996-12-03 | 2008-06-16 | Amgen Fremont Inc. | COMPLETELY HUMAN ANTIBODY THAT JOINS THE EGFR RECEIVER. |
| IL136544A0 (en) | 1997-12-05 | 2001-06-14 | Scripps Research Inst | Humanization of murine antibody |
| BR112014012819B1 (en) * | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | ANTI-PD-L1 ANTIBODY OR ANTIGEN BINDING FRAGMENT AND COMPOSITION |
| HUE046674T2 (en) * | 2013-09-11 | 2020-03-30 | Medimmune Ltd | Anti-b7-h1 antibodies for treating tumors |
| SG10202007111TA (en) * | 2014-07-15 | 2020-09-29 | Genentech Inc | Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors |
| US10800846B2 (en) * | 2015-02-26 | 2020-10-13 | Merck Patent Gmbh | PD-1/PD-L1 inhibitors for the treatment of cancer |
| WO2016205277A1 (en) * | 2015-06-16 | 2016-12-22 | Merck Patent Gmbh | Pd-l1 antagonist combination treatments |
-
2017
- 2017-05-22 SG SG11201810423XA patent/SG11201810423XA/en unknown
- 2017-05-22 JP JP2018561278A patent/JP2019516748A/en active Pending
- 2017-05-22 RU RU2018145184A patent/RU2018145184A/en not_active Application Discontinuation
- 2017-05-22 US US16/304,338 patent/US20190144545A1/en not_active Abandoned
- 2017-05-22 EP EP17724821.8A patent/EP3464356A1/en not_active Withdrawn
- 2017-05-22 WO PCT/EP2017/062213 patent/WO2017202744A1/en unknown
- 2017-05-22 CA CA3025391A patent/CA3025391A1/en not_active Abandoned
- 2017-05-22 MX MX2018014435A patent/MX2018014435A/en unknown
- 2017-05-22 CN CN201780032522.1A patent/CN109195989A/en active Pending
- 2017-05-22 KR KR1020187037522A patent/KR20190012201A/en not_active Application Discontinuation
- 2017-05-22 BR BR112018073920-0A patent/BR112018073920A2/en not_active Application Discontinuation
- 2017-05-22 AU AU2017269675A patent/AU2017269675A1/en not_active Abandoned
- 2017-05-25 TW TW106117304A patent/TW201800108A/en unknown
-
2018
- 2018-11-21 IL IL263178A patent/IL263178A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3025391A1 (en) | 2017-11-30 |
| IL263178A (en) | 2018-12-31 |
| US20190144545A1 (en) | 2019-05-16 |
| EP3464356A1 (en) | 2019-04-10 |
| JP2019516748A (en) | 2019-06-20 |
| CN109195989A (en) | 2019-01-11 |
| RU2018145184A (en) | 2020-06-26 |
| BR112018073920A2 (en) | 2019-02-26 |
| MX2018014435A (en) | 2019-04-15 |
| TW201800108A (en) | 2018-01-01 |
| AU2017269675A1 (en) | 2019-01-17 |
| KR20190012201A (en) | 2019-02-08 |
| WO2017202744A1 (en) | 2017-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201810423XA (en) | Pd-1 / pd-l1 inhibitors for cancer treatment | |
| SG11201809559UA (en) | Substituted pyridines as inhibitors of dnmt1 | |
| SG11201901126UA (en) | Combination therapy for cancer | |
| SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201907583TA (en) | Methods for treating complement-mediated diseases and disorders | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201807593TA (en) | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
| SG11201809594WA (en) | Nicotine particles and compositions | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201909064RA (en) | Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201804123VA (en) | Modulators of kv3 channels to treat pain | |
| SG11201808525UA (en) | Anti-complement factor bb antibodies and uses thereof | |
| SG11201810333UA (en) | Combination of anti-cd20 antibody, p13 kinase-delta selective inhibitor, and btk inhibitor to treat b-cell proliferative disorders | |
| SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer |